Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.34 |
| ▸ | MPL | P40238 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102609 | 0.91 | SPHK1 (0.37) | SPHK1RARBFFAR4SPHK2 | |
| SCHEMBL17192522 | 0.81 | SPHK1 (0.46) | SPHK1RARBFASNFFAR4SPHK2 | |
| SCHEMBL19844743 | 0.81 | SPHK1 (0.46) | SPHK1RARBFASNFFAR4SPHK2 | |
| SCHEMBL20111292 | 0.80 | ESR2 (0.35) | FASNFFAR4 | |
| SCHEMBL20111097 | 0.78 | SPHK1 (0.51) | SPHK1RARBFASNFFAR4SPHK2 | |
| SCHEMBL10949990 | 0.77 | SPHK1 (0.44) | SPHK1RARBFFAR4SPHK2 | |
| SCHEMBL10949984 | 0.77 | SPHK1 (0.44) | SPHK1RARBFFAR4SPHK2 | |
| SCHEMBL10947235 | 0.76 | SPHK1 (0.43) | SPHK1RARBFFAR4SPHK2 | |
| SCHEMBL10947243 | 0.76 | SPHK1 (0.43) | SPHK1RARBFFAR4SPHK2 | |
| SCHEMBL15279088 | 0.76 | APP (0.40) | SPHK1RARBFASNFFAR4SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | SPHK1 1401/4885RARB 1858/4885FASN 2680/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | SPHK1 1401/4885RARB 1858/4885FASN 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.